MX2011001261A - Composicion parenteral que comprende microesferas con un diametro entre 10 y 20 micrometros. - Google Patents
Composicion parenteral que comprende microesferas con un diametro entre 10 y 20 micrometros.Info
- Publication number
- MX2011001261A MX2011001261A MX2011001261A MX2011001261A MX2011001261A MX 2011001261 A MX2011001261 A MX 2011001261A MX 2011001261 A MX2011001261 A MX 2011001261A MX 2011001261 A MX2011001261 A MX 2011001261A MX 2011001261 A MX2011001261 A MX 2011001261A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- tissue
- particles
- igf
- growth factor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 113
- 239000004005 microsphere Substances 0.000 title claims description 104
- 239000002245 particle Substances 0.000 claims abstract description 155
- 238000009472 formulation Methods 0.000 claims abstract description 80
- 239000004480 active ingredient Substances 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 66
- 210000000056 organ Anatomy 0.000 claims abstract description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 39
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 34
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 230000001839 systemic circulation Effects 0.000 claims abstract description 16
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 13
- 238000007911 parenteral administration Methods 0.000 claims abstract description 7
- 230000008685 targeting Effects 0.000 claims abstract description 5
- 210000001519 tissue Anatomy 0.000 claims description 146
- 210000000130 stem cell Anatomy 0.000 claims description 117
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 86
- 210000002216 heart Anatomy 0.000 claims description 79
- 239000003102 growth factor Substances 0.000 claims description 42
- 230000000747 cardiac effect Effects 0.000 claims description 40
- 230000008929 regeneration Effects 0.000 claims description 39
- 238000011069 regeneration method Methods 0.000 claims description 39
- 208000010125 myocardial infarction Diseases 0.000 claims description 38
- 238000009826 distribution Methods 0.000 claims description 28
- 230000000717 retained effect Effects 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 16
- 230000004087 circulation Effects 0.000 claims description 16
- 230000000302 ischemic effect Effects 0.000 claims description 16
- 230000000638 stimulation Effects 0.000 claims description 14
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 13
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 13
- 210000005003 heart tissue Anatomy 0.000 claims description 12
- 230000002792 vascular Effects 0.000 claims description 12
- 230000017531 blood circulation Effects 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 11
- 230000001154 acute effect Effects 0.000 claims description 10
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 9
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 9
- 102000003951 Erythropoietin Human genes 0.000 claims description 8
- 108090000394 Erythropoietin Proteins 0.000 claims description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 229940105423 erythropoietin Drugs 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 8
- 238000001361 intraarterial administration Methods 0.000 claims description 7
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 230000003412 degenerative effect Effects 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 206010028851 Necrosis Diseases 0.000 claims description 4
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 230000034994 death Effects 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 3
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 3
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 3
- 108010023082 activin A Proteins 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 210000002536 stromal cell Anatomy 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 8
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 6
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 6
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 6
- 102000004230 Neurotrophin 3 Human genes 0.000 claims 6
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 6
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 6
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 6
- 229940053128 nerve growth factor Drugs 0.000 claims 6
- 229940032018 neurotrophin 3 Drugs 0.000 claims 6
- 229940097998 neurotrophin 4 Drugs 0.000 claims 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 4
- 101800003838 Epidermal growth factor Proteins 0.000 claims 4
- 102000004858 Growth differentiation factor-9 Human genes 0.000 claims 4
- 108090001086 Growth differentiation factor-9 Proteins 0.000 claims 4
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 4
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 4
- 108010056852 Myostatin Proteins 0.000 claims 4
- 102000036693 Thrombopoietin Human genes 0.000 claims 4
- 108010041111 Thrombopoietin Proteins 0.000 claims 4
- 229940116977 epidermal growth factor Drugs 0.000 claims 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 4
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 3
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 2
- 101710111489 Neurotrophin 1 Proteins 0.000 claims 2
- 102100037765 Periostin Human genes 0.000 claims 2
- 101710199268 Periostin Proteins 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 101150019331 FGF2 gene Proteins 0.000 claims 1
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 claims 1
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 1
- 230000006727 cell loss Effects 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 185
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 98
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 95
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 82
- 210000000107 myocyte Anatomy 0.000 description 70
- 241001465754 Metazoa Species 0.000 description 67
- 210000004165 myocardium Anatomy 0.000 description 56
- 206010061216 Infarction Diseases 0.000 description 52
- 230000007574 infarction Effects 0.000 description 41
- 241000282887 Suidae Species 0.000 description 37
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 36
- 230000001172 regenerating effect Effects 0.000 description 34
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 32
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 32
- 230000002107 myocardial effect Effects 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 210000002064 heart cell Anatomy 0.000 description 27
- 210000004413 cardiac myocyte Anatomy 0.000 description 24
- 238000002560 therapeutic procedure Methods 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 22
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 239000011859 microparticle Substances 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 230000004913 activation Effects 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 210000003205 muscle Anatomy 0.000 description 18
- 206010000891 acute myocardial infarction Diseases 0.000 description 17
- 210000004351 coronary vessel Anatomy 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 230000004069 differentiation Effects 0.000 description 16
- 239000003446 ligand Substances 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- 210000003748 coronary sinus Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000004793 Polystyrene Substances 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 229920002223 polystyrene Polymers 0.000 description 12
- 210000001367 artery Anatomy 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 210000002889 endothelial cell Anatomy 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000002243 precursor Substances 0.000 description 10
- 210000002027 skeletal muscle Anatomy 0.000 description 10
- 230000002861 ventricular Effects 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 9
- 210000002837 heart atrium Anatomy 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 230000004936 stimulating effect Effects 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 102000007469 Actins Human genes 0.000 description 8
- 108010085238 Actins Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 8
- 229920000615 alginic acid Polymers 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 229920000867 polyelectrolyte Polymers 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 206010019280 Heart failures Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 210000002565 arteriole Anatomy 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 210000005240 left ventricle Anatomy 0.000 description 7
- 229920000747 poly(lactic acid) Polymers 0.000 description 7
- -1 polypropylene Polymers 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000007634 remodeling Methods 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 108010047303 von Willebrand Factor Proteins 0.000 description 7
- 102100036537 von Willebrand factor Human genes 0.000 description 7
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 6
- 208000001778 Coronary Occlusion Diseases 0.000 description 6
- 206010011086 Coronary artery occlusion Diseases 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 101150114527 Nkx2-5 gene Proteins 0.000 description 6
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- 229940072056 alginate Drugs 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000004626 polylactic acid Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 102000003952 Caspase 3 Human genes 0.000 description 5
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 230000003394 haemopoietic effect Effects 0.000 description 5
- 230000004217 heart function Effects 0.000 description 5
- 229920000669 heparin Polymers 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 210000004504 adult stem cell Anatomy 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 230000003021 clonogenic effect Effects 0.000 description 4
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 230000009260 cross reactivity Effects 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000002592 echocardiography Methods 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 230000003176 fibrotic effect Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 210000000663 muscle cell Anatomy 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000000879 optical micrograph Methods 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000003076 paracrine Effects 0.000 description 4
- 210000004738 parenchymal cell Anatomy 0.000 description 4
- 229940020573 plavix Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000011287 therapeutic dose Methods 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 101150031329 Ets1 gene Proteins 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 101001053263 Homo sapiens Insulin gene enhancer protein ISL-1 Proteins 0.000 description 3
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 3
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 3
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 description 3
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 3
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000001269 cardiogenic effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 210000000555 contractile cell Anatomy 0.000 description 3
- 230000008828 contractile function Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 102000044162 human IGF1 Human genes 0.000 description 3
- 230000001969 hypertrophic effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000003314 quadriceps muscle Anatomy 0.000 description 3
- 230000009719 regenerative response Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000005241 right ventricle Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 101150088952 IGF1 gene Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 2
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 101150086694 SLC22A3 gene Proteins 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 101001050928 Sus scrofa UMP-CMP kinase Proteins 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 2
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 2
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 2
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 2
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000009756 muscle regeneration Effects 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000001178 neural stem cell Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940052907 telazol Drugs 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BUOYTFVLNZIELF-UHFFFAOYSA-N 2-phenyl-1h-indole-4,6-dicarboximidamide Chemical compound N1C2=CC(C(=N)N)=CC(C(N)=N)=C2C=C1C1=CC=CC=C1 BUOYTFVLNZIELF-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100033267 Early placenta insulin-like peptide Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101150007884 Gata6 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 102100034223 Golgi apparatus protein 1 Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 108091008603 HGF receptors Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 101000998777 Homo sapiens Early placenta insulin-like peptide Proteins 0.000 description 1
- 101100449731 Homo sapiens GLG1 gene Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 101150002416 Igf2 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710186630 Insulin-1 Proteins 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 101150044441 PECAM1 gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101100439271 Schizosaccharomyces pombe (strain 972 / ATCC 24843) cfr1 gene Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000008822 capillary blood flow Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 238000007786 electrostatic charging Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003897 hepatic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005244 lower chamber Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 230000007576 microinfarct Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- DDRCIGNRLHTTIW-UHFFFAOYSA-N n-(4-amino-2,5-dimethoxyphenyl)benzamide Chemical compound C1=C(N)C(OC)=CC(NC(=O)C=2C=CC=CC=2)=C1OC DDRCIGNRLHTTIW-UHFFFAOYSA-N 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036276 paracrine stimulus Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000013424 sirius red staining Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000012859 tissue stain Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- NFMWFGXCDDYTEG-UHFFFAOYSA-N trimagnesium;diborate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]B([O-])[O-].[O-]B([O-])[O-] NFMWFGXCDDYTEG-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0814302.6A GB0814302D0 (en) | 2008-08-05 | 2008-08-05 | Compounds and methods |
| PCT/EP2009/060171 WO2010015665A2 (en) | 2008-08-05 | 2009-08-05 | Compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011001261A true MX2011001261A (es) | 2011-08-08 |
Family
ID=39846672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011001261A MX2011001261A (es) | 2008-08-05 | 2009-08-05 | Composicion parenteral que comprende microesferas con un diametro entre 10 y 20 micrometros. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20120195939A1 (https=) |
| EP (1) | EP2323626B1 (https=) |
| JP (1) | JP5623400B2 (https=) |
| KR (1) | KR101639827B1 (https=) |
| CN (1) | CN102170868A (https=) |
| AU (1) | AU2009279086B2 (https=) |
| BR (1) | BRPI0917571B1 (https=) |
| CA (1) | CA2732785C (https=) |
| CL (1) | CL2011000244A1 (https=) |
| ES (1) | ES2677005T3 (https=) |
| GB (1) | GB0814302D0 (https=) |
| MX (1) | MX2011001261A (https=) |
| WO (1) | WO2010015665A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| GB0814302D0 (en) | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
| WO2014022685A1 (en) | 2012-08-03 | 2014-02-06 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Recruitment of mesenchymal cells using controlled release systems |
| AU2013302799B2 (en) | 2012-08-13 | 2018-03-01 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| WO2014066545A1 (en) * | 2012-10-26 | 2014-05-01 | Cedars-Sinai Medical Center | Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration |
| ES2606636T3 (es) * | 2013-01-24 | 2017-03-24 | Pierre Fabre Médicament S.A.S. | Composición que comprende un antagomir encapsulado |
| WO2014114465A1 (en) * | 2013-01-24 | 2014-07-31 | Bernardo Nadal-Ginard | Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof |
| CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| CN104650333B (zh) * | 2015-02-05 | 2016-08-24 | 浙江大学 | 聚乳酸/氢化聚丁二烯热塑性超分子弹性体及其制备方法 |
| WO2016139590A1 (en) * | 2015-03-02 | 2016-09-09 | Accurate Medical Therapeutics Ltd. | Embolization particulates for occluding a blood vessel |
| EP3277363B1 (en) | 2015-03-30 | 2019-06-19 | TARIS Biomedical LLC | Devices for local delivery of drug to upper urinary tract |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| ES2865433T3 (es) | 2016-05-04 | 2021-10-15 | Accurate Medical Therapeutics Ltd | Cabezal de microcatéter de embolización que tiene un patrón ranurado |
| WO2017210652A1 (en) | 2016-06-03 | 2017-12-07 | Cedars-Sinai Medical Center | Cdc-derived exosomes for treatment of ventricular tachyarrythmias |
| EP3471705A1 (en) | 2016-06-20 | 2019-04-24 | Virbac | Method and apparatus for preparing a micro-particles composition |
| US11541078B2 (en) | 2016-09-20 | 2023-01-03 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| EP4699658A2 (en) | 2017-04-19 | 2026-02-25 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| WO2019087191A1 (en) | 2017-11-02 | 2019-05-09 | Accurate Medical Therapeutics Ltd. | Embolization catheter with integral filter |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| US12414999B2 (en) * | 2018-01-12 | 2025-09-16 | President And Fellows Of Harvard College | Compositions and methods relating to macrophages and/or monocytes with adhered particles |
| US12146137B2 (en) | 2018-02-05 | 2024-11-19 | Cedars-Sinai Medical Center | Methods for therapeutic use of exosomes and Y-RNAS |
| EP3972500B1 (en) | 2019-05-23 | 2025-04-30 | Accurate Medical Therapeutics Ltd. | Embolization catheter for reflux free delivery of microspheres |
| US20240082167A1 (en) * | 2021-01-22 | 2024-03-14 | University Of Connecticut | Synthetic artificial stem cells (sasc) |
| EP4658295A2 (en) * | 2023-02-02 | 2025-12-10 | Silver Creek Pharmaceuticals, Inc. | Methods of treatment using igf-1 chimeric proteins |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| PT796090E (pt) | 1994-12-16 | 2003-07-31 | Elan Drug Delivery Ltd | Microparticulas reticuladas e sua utilizacao como veiculos terapeuticos |
| US5942253A (en) | 1995-10-12 | 1999-08-24 | Immunex Corporation | Prolonged release of GM-CSF |
| CA2161863A1 (en) | 1995-10-31 | 1997-05-01 | Michael Vivian Sefton | Angiogenic material and uses thereof |
| US6511477B2 (en) | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
| EP0977593A1 (en) | 1997-04-24 | 2000-02-09 | Nycomed Imaging A/S | Embolus therapy using insoluble microparticles or vesicles containing contrast agents |
| EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
| AU1384199A (en) * | 1997-11-07 | 1999-05-31 | Chiron Corporation | Method for producing igf-1 sustained-release formulations |
| JP2002527401A (ja) | 1998-10-13 | 2002-08-27 | カイロン コーポレイション | Ｆｇｆの脈管形成的に有効な単位用量および投与方法 |
| WO2000028969A2 (en) | 1998-11-18 | 2000-05-25 | University Of Florida | Methods for preparing coated drug particles and pharmaceutical formulations thereof |
| US7651703B2 (en) | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| US7547674B2 (en) | 2001-06-06 | 2009-06-16 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| JPWO2003059375A1 (ja) * | 2002-01-17 | 2005-05-19 | 株式会社カルディオ | 組織再生複合療法 |
| US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
| WO2004022000A2 (en) | 2002-09-05 | 2004-03-18 | Ambrose Catherine G | Antibiotic microspheres for treatment of infections and osteomyelitis |
| WO2004084819A2 (en) * | 2003-03-19 | 2004-10-07 | University Of Kentucky Research Foundation | Poly(acryloyl-hydroxyethyl starch)-plga composite microspheres |
| US20050142205A1 (en) * | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| WO2005007122A2 (en) * | 2003-07-18 | 2005-01-27 | Oakwood Laboratories, L.L.C. | Polymer stabilization |
| JP4532092B2 (ja) * | 2003-09-30 | 2010-08-25 | 泰彦 田畑 | 血管新生剤 |
| WO2005055949A2 (en) | 2003-12-09 | 2005-06-23 | The Children's Hospital Of Philadelphia | Sustained release preparations composed of biocompatible complex microparticles |
| JP5048323B2 (ja) * | 2004-03-31 | 2012-10-17 | 株式会社ツーセル | 損傷組織の治療剤と治療方法 |
| US7854944B2 (en) | 2004-12-17 | 2010-12-21 | Advanced Cardiovascular Systems, Inc. | Tissue regeneration |
| ES2273572B1 (es) * | 2005-05-04 | 2008-04-01 | Universidad De Sevilla | Procedimiento de preparacion de particulas de tamaño micro y nanometrico con productos labiles y particulas obtenidas. |
| WO2007028053A2 (en) | 2005-09-02 | 2007-03-08 | X-Cell Medical Incorporated | Methods of treating and preventing cardiac disorders |
| KR100718329B1 (ko) | 2005-09-08 | 2007-05-14 | 광주과학기술원 | 다당류로 기능화된 수화젤막을 가지는 나노입자와 이를포함하는 서방형 약물전달시스템 및 그 제조방법 |
| EP1976547A1 (en) * | 2005-11-11 | 2008-10-08 | Vascular Biosciences | R-ras activity in vascular regulation |
| AU2006315601A1 (en) * | 2005-11-14 | 2007-05-24 | Enterprise Partners Venture Capital | Stem cell factor therapy for tissue injury |
| CU23388B6 (es) | 2006-01-31 | 2009-07-16 | Ct Ingenieria Genetica Biotech | Composición farmacéutica de microesferas para prevenir la amputación del pie diabético |
| ES2459743T3 (es) | 2006-10-19 | 2014-05-12 | Ono Pharmaceutical Co., Ltd. | Preparación de liberación sostenida para terapia de regeneración tisular |
| WO2008108736A1 (en) | 2007-03-06 | 2008-09-12 | Agency For Science, Technology And Research | Particles for delivery of bioactive factors |
| EP2244697A1 (en) | 2008-01-29 | 2010-11-03 | Shire Human Genetic Therapies, Inc. | Therapeutic compositions |
| US8642333B2 (en) | 2008-02-04 | 2014-02-04 | Massachusetts Institute Of Technology | Particulate delivery vehicles for embryoid bodies |
| US20090297621A1 (en) * | 2008-06-03 | 2009-12-03 | Abbott Cardiovascular Systems Inc. | Microparticles For The Treatment Of Disease |
| GB0814302D0 (en) | 2008-08-05 | 2008-10-01 | Coretherapix Slu | Compounds and methods |
-
2008
- 2008-08-05 GB GBGB0814302.6A patent/GB0814302D0/en not_active Ceased
-
2009
- 2009-08-05 WO PCT/EP2009/060171 patent/WO2010015665A2/en not_active Ceased
- 2009-08-05 CN CN2009801391387A patent/CN102170868A/zh active Pending
- 2009-08-05 ES ES09781530.2T patent/ES2677005T3/es active Active
- 2009-08-05 JP JP2011521575A patent/JP5623400B2/ja not_active Expired - Fee Related
- 2009-08-05 AU AU2009279086A patent/AU2009279086B2/en not_active Ceased
- 2009-08-05 CA CA2732785A patent/CA2732785C/en active Active
- 2009-08-05 BR BRPI0917571-7A patent/BRPI0917571B1/pt not_active IP Right Cessation
- 2009-08-05 MX MX2011001261A patent/MX2011001261A/es active IP Right Grant
- 2009-08-05 EP EP09781530.2A patent/EP2323626B1/en active Active
- 2009-08-05 KR KR1020117004837A patent/KR101639827B1/ko not_active Expired - Fee Related
-
2011
- 2011-02-04 CL CL2011000244A patent/CL2011000244A1/es unknown
-
2012
- 2012-03-20 US US13/425,041 patent/US20120195939A1/en not_active Abandoned
-
2013
- 2013-01-08 US US13/736,267 patent/US20130189321A1/en not_active Abandoned
- 2013-04-30 US US13/873,812 patent/US8846099B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0917571A2 (pt) | 2020-08-11 |
| AU2009279086B2 (en) | 2014-05-22 |
| JP5623400B2 (ja) | 2014-11-12 |
| KR20110051212A (ko) | 2011-05-17 |
| AU2009279086A1 (en) | 2010-02-11 |
| ES2677005T3 (es) | 2018-07-27 |
| CN102170868A (zh) | 2011-08-31 |
| US20130189321A1 (en) | 2013-07-25 |
| CL2011000244A1 (es) | 2011-07-15 |
| US20130315997A1 (en) | 2013-11-28 |
| JP2011529946A (ja) | 2011-12-15 |
| US8846099B2 (en) | 2014-09-30 |
| EP2323626A2 (en) | 2011-05-25 |
| BRPI0917571B1 (pt) | 2022-01-04 |
| CA2732785A1 (en) | 2010-02-11 |
| WO2010015665A2 (en) | 2010-02-11 |
| KR101639827B1 (ko) | 2016-07-14 |
| GB0814302D0 (en) | 2008-10-01 |
| CA2732785C (en) | 2016-11-22 |
| US20120195939A1 (en) | 2012-08-02 |
| WO2010015665A3 (en) | 2010-10-07 |
| EP2323626B1 (en) | 2018-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2323626B1 (en) | Parenteral composition comprising microspheres with a diameter between 10 and 20 microns | |
| US20130309304A1 (en) | Compounds and methods | |
| Jin et al. | Application of stem cells in regeneration medicine | |
| Chen et al. | Biomaterial-based regenerative therapeutic strategies for spinal cord injury | |
| US20240315979A1 (en) | Purified exosome products, method of making, and methods of using | |
| Sun et al. | Neurotrophin-3-loaded multichannel nanofibrous scaffolds promoted anti-inflammation, neuronal differentiation, and functional recovery after spinal cord injury | |
| Zhang et al. | PDGF-BB/SA/Dex injectable hydrogels accelerate BMSC-mediated functional full thickness skin wound repair by promoting angiogenesis | |
| Shin et al. | Co-delivery of vascular endothelial growth factor and angiopoietin-1 using injectable microsphere/hydrogel hybrid systems for therapeutic angiogenesis | |
| Umar | Stem cell’s secretome delivery systems | |
| Erel-Akbaba et al. | Octaarginine functionalized nanoencapsulated system: In vitro and in vivo evaluation of bFGF loaded formulation for wound healing | |
| Shi et al. | Advances in nanotherapy for targeting senescent cells | |
| Chen et al. | Preparation of adriamycin gelatin microsphere‐loaded decellularized periosteum that is cytotoxic to human osteosarcoma cells | |
| US20050214377A1 (en) | Microparticles for cell delivery | |
| Assunção-Silva et al. | Nanoengineered biomaterials for spinal cord regeneration | |
| Sable et al. | Applications of electrospraying in tissue repair and regeneration | |
| US20240325610A1 (en) | Drug coating, drug-coated balloon and preparation method thereof | |
| Ho | Local delivery of PACAP attenuates inflammation and promotes functional recovery in a mouse model of stroke injury | |
| Sanju et al. | Micro and nanoparticles for the delivery of growth factors in diabetic wounds | |
| Sava | The development of a hydrogel-based regenerative therapy for brain tissue repair and functional recovery following ischaemic stroke | |
| Elliott Donaghue | Controlled Delivery of Therapeutic Proteins to the Injured Spinal Cord | |
| Shultz | Biomaterials-Based Drug Delivery Systems for Treating Spinal Cord Injury | |
| CN119633170A (zh) | 一种调控局部炎症微环境促神经再生的复合微球的制备方法 | |
| Shah et al. | Engineering Layer-by-Layer Thin Films for Multiscale and Multidrug Delivery Applications | |
| Pakulska | Combined Delivery of Chondroitinase ABC (ChABC) and Stromal Cell Derived Factor 1α (SDF1α) for Spinal Cord Regeneration | |
| Johnson | Controlled delivery of bioactive factors for tissue regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |